Posters

      Quantifying the Level of Knowledge of Health Risks for New Tobacco Products: Development of a Measurement Certainty Index

      Kallischnigg, G.; Weitkunat, R.; Browne, H.; Smith, M.; Sanders, E.; Dempsey, R.; H-Urban, H-J. Urban.
      Conference date
      Dec 7, 2008
      Conference name
      Society for Risk Analysis (SRA) 2008
      Link to more information
      Link to more information
      Topic
      Summary

      Epidemiological risk assessment of new, potentially reduced-risk tobacco products (PRRTP) relates use of these products to morbidity and mortality risks. It quantifies the probability of developing a disease under specific exposure conditions. Although an epidemiological approach is the benchmark for health-risk assessment of tobacco products, it is often not applicable for risk assessment of new and innovative products where it is necessary to provide reliable predictive estimates of comparative risk prior to launch on a market. This is especially true when there is a long latency period between exposure and health outcome. The aim of this paper is to introduce the measurement certainty index (MCI) as a method based on objective rules to determine the level of certainty provided by a given dataset in a risk assessment context. The level of certainty depends on methodological aspects as well as on the underlying data, and the two core dimensions of the mci are reliability and validity. While reliability of measurement is primarily a technical issue, validity is more complex. The MCI is a quantitative measure of empirical evidence weighting different criteria of reliability and validity with respect to the level of certainty of a risk assessment. Application of such an index can help with both the retrospective assessment of existing data sets and the prospective design of assessment strategies to determine the probability of reduced risk prior to launch (and subsequent collection of epidemiological data).

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.